Melanoma: genes and variants
Explore variant evidence for Melanoma across 17 analyzed proteins (BRAF, CDKN2A, ARID2, CTLA4, IFNAR1 and 12 more). Linked ClinVar records include 3 pathogenic or likely pathogenic variants, 1 variants of uncertain significance and 0 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-10-22. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Melanoma
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
2 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in BRAF have source records linked to Melanoma. Association strength is not clinical gene validity.
CDKN2A: Tumor suppressor ARF
The ARF product of CDKN2A is a tumor-suppressor protein that binds MDM2 and helps preserve p53 activity. By promoting cell-cycle arrest and apoptosis, it provides an important barrier to uncontrolled cell growth from within the nucleolus.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CDKN2A have source records linked to Melanoma. Association strength is not clinical gene validity.
ARID2: AT-rich interactive domain-containing protein 2
It contributes DNA targeting and regulatory specificity to PBAF chromatin-remodeling complexes. Somatic loss-of-function alterations occur in melanoma, liver cancer, and other tumors, while germline variants can cause a Coffin-Siris-spectrum neurodevelopmental disorder.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ARID2 have source records linked to Melanoma. Association strength is not clinical gene validity.
CTLA4: Cytotoxic T-lymphocyte protein 4
It restrains T-cell activation by competing with CD28 for CD80 and CD86 and by delivering inhibitory signals after immune activation. Haploinsufficiency causes immune dysregulation with autoimmunity and lymphoproliferation, while therapeutic blockade enhances antitumor immunity.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CTLA4 have source records linked to Melanoma. Association strength is not clinical gene validity.
IFNAR1: Interferon alpha/beta receptor 1
Together with IFNAR2, it detects type I interferons and activates JAK-STAT antiviral and immunoregulatory programs. Loss-of-function can impair antiviral defense, while excessive pathway activation contributes to interferon-driven inflammatory disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IFNAR1 have source records linked to Melanoma. Association strength is not clinical gene validity.
IFNAR2: Interferon alpha/beta receptor 2
It provides the high-affinity ligand-binding component of the type I interferon receptor complex and triggers antiviral JAK-STAT signaling with IFNAR1. Biallelic loss-of-function variants can predispose to severe viral infections, including critical COVID-19 in some individuals.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IFNAR2 have source records linked to Melanoma. Association strength is not clinical gene validity.
IRF4: Interferon regulatory factor 4
It controls differentiation and function of B cells, plasma cells, T cells, and other immune lineages in a context-dependent manner. Germline variants can cause immunodeficiency, while rearrangements or abnormal expression drive several lymphoid malignancies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in IRF4 have source records linked to Melanoma. Association strength is not clinical gene validity.
LAG3: Lymphocyte activation gene 3 protein
It restrains activated and chronically stimulated T cells and contributes to immune tolerance and T-cell exhaustion. Its coexpression with other inhibitory receptors in tumors makes LAG-3 an established immune-checkpoint target in cancer therapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in LAG3 have source records linked to Melanoma. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K1 have source records linked to Melanoma. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K2 have source records linked to Melanoma. Association strength is not clinical gene validity.
MITF: Microphthalmia-associated transcription factor
A transcription factor that drives melanocyte survival, pigment production, and melanosome formation. Pathogenic variants can cause Waardenburg syndrome type 2A or Tietz syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MITF have source records linked to Melanoma. Association strength is not clinical gene validity.
NF1: Neurofibromin
It accelerates conversion of active RAS-GTP to inactive RAS-GDP and therefore restrains RAS-MAPK signaling. Loss-of-function variants cause neurofibromatosis type 1 with neurofibromas, pigmentary features, learning difficulties, and increased tumor risk.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NF1 have source records linked to Melanoma. Association strength is not clinical gene validity.
NRAS: GTPase NRas
Its active GTP-bound state drives RAF-MEK-ERK and PI3K signaling downstream of growth-factor receptors. Somatic activating variants are common drivers of melanoma, leukemia, and other cancers, while germline activating variants can cause Noonan syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NRAS have source records linked to Melanoma. Association strength is not clinical gene validity.
OCA2: P protein
It supports chloride conductance in melanosomes, helping establish the pH needed for tyrosinase activity and melanin production. Biallelic loss-of-function variants cause oculocutaneous albinism type 2, while common regulatory variation contributes to differences in eye, skin, and hair pigmentation.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in OCA2 have source records linked to Melanoma. Association strength is not clinical gene validity.
PDCD1: Programmed cell death protein 1
PDCD1 is an inhibitory receptor on activated T cells that binds PD-L1 and PD-L2. Its signaling helps maintain immune tolerance by restraining T-cell activation, making the protein important in autoimmunity and cancer immunotherapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDCD1 have source records linked to Melanoma. Association strength is not clinical gene validity.
PTEN: Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
A lipid and protein phosphatase that removes phosphate groups from signaling molecules, especially PIP3. By opposing the PI3K-AKT pathway, it limits cell growth and survival signals, and PTEN variants are associated with Cowden syndrome and multiple cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PTEN have source records linked to Melanoma. Association strength is not clinical gene validity.
RAC1: Ras-related C3 botulinum toxin substrate 1
It acts as a molecular switch controlling actin remodeling, cell migration, membrane trafficking, reactive-oxygen production, and developmental signaling. De novo activating or loss-of-function variants can cause neurodevelopmental syndromes with abnormal brain growth and craniofacial features.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RAC1 have source records linked to Melanoma. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): CDK12 and DNMT3A.
ClinVar pathogenic and likely pathogenic variants linked to Melanoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| BRAF L525P | 525 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF D638E | 638 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| CDKN2A R115L | 115 | Pathogenic / likely pathogenic (★★) |
Same protein, different disease
- RASopathy also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Melanoma variants (36 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Melanoma variants (26 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Melanoma variants (17 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Melanoma variants (11 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Melanoma variants (10 pathogenic / likely pathogenic).
- Familial melanoma also has ClinVar records linked to CDKN2A variants; they fall mostly in different places as the Melanoma variants (15 pathogenic / likely pathogenic).
- Melanoma-pancreatic cancer syndrome also has ClinVar records linked to CDKN2A variants; they fall mostly in different places as the Melanoma variants (11 pathogenic / likely pathogenic).
- Melanoma, cutaneous malignant also has ClinVar records linked to CDKN2A variants; they fall mostly in different places as the Melanoma variants (6 pathogenic / likely pathogenic).
- Melanoma and neural system tumor syndrome also has ClinVar records linked to CDKN2A variants; they fall mostly in different places as the Melanoma variants (5 pathogenic / likely pathogenic).
Diseases related to Melanoma
- Non-small cell lung carcinoma, also linked to BRAF, CDKN2A, CTLA4, MAP2K1 and 1 more
- Multiple myeloma, also linked to BRAF, IFNAR1, IFNAR2, IRF4 and 1 more
- Hypertrophic cardiomyopathy, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- RASopathy, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Noonan syndrome, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Noonan syndrome and Noonan-related syndrome, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Cardiofaciocutaneous syndrome, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Costello syndrome, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Hepatocellular carcinoma, also linked to ARID2, BRAF, CDKN2A and CTLA4
- Neurofibromatosis, also linked to MAP2K1, MAP2K2 and NF1
- Cardio-facio-cutaneous syndrome, also linked to BRAF, MAP2K1 and MAP2K2
- Melanoma, cutaneous malignant, also linked to BRAF, CDKN2A and MITF
Frequently asked questions
Which genes have records linked to Melanoma?
This view contains 17 analyzed proteins: BRAF, CDKN2A, ARID2, CTLA4, IFNAR1 and 12 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 3 pathogenic or likely pathogenic variants, 1 variants of uncertain significance and 0 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 6 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center